Novartis has increased its drug stocks in the US and plans investments of 23 billion dollars, preparing for possible tariffs imposed by the Trump administration.

The CEO of Novartis, Vas Narasimhan, announced that the Swiss pharmaceutical group has significantly increased its drug stocks in the United States, ensuring that they will be sufficient until 2026. Although pharmaceutical products are currently exempt from the 39% tariffs imposed by Washington, the sector is awaiting the results of an investigation that could bring additional taxes. Novartis plans to invest $23 billion in the U.S. and intends to locally produce important medications, with the first shifts expected in two years.